Skip to main contentrtttttt Skip to main content
Integrative Psychiatry

Shamans or Shrinks? Comparing Ceremonial and Psychotherapeutic Psychedelic Journeys

By November 7, 2024No Comments

Psychedelics are widely recognized as a therapeutic tool, thanks to decades of research. As the Western medical model catches up with longstanding ancient practices of working with psychedelics, two approaches are emerging in this space: “ceremonial” experiences and “clinical” psychedelic-assisted therapy. While both incorporate similar medicines and pharmacological effects, the felt experience all will differ dramatically through their originations, context, and applications. 

Sitting in Ceremony

Ritual use of psychedelics has deep roots, stretching back for millennia in various cultures around the world. In ancient history, psychedelics were likely confined to sacred contexts. Today, these rituals are often facilitated by trained spiritual leaders who hold the wisdom of their lineage, serving as guides and protectors for those embarking on their inner journeys.

One of the distinctions of the ceremonial setting is the underlying framework. Rather than viewing mental health challenges through the lens of a “disordered” psyche, the ceremonial perspective often sees suffering as stemming from spiritual disconnection or imbalances in key relationships. The intention is not to “fix” the individual, but to facilitate a shift in the relationships with the sacred, the natural world, and the essence of one’s being within a community.

This difference in perspective can manifest in the approach to the experience itself. In ceremony, the focus tends to be on the collective, with participants often working in a group setting, supported by the rituals, songs, and prayers. Often, the psychedelic effects of the sacrament are downplayed within other healing elements that make up the ceremony, such as songs, chanting, music, and even dancing. Communitas is a foundation of the ceremonial purpose, as these events were usually intended to support the wellbeing of the larger social network; after all, survival of the human species has always relied on societies. The emphasis is on attending to relationships between the individual, the medicine, and the collective, and in many some shamanic healing traditions, non-psychedelic “plant teachers” may be offered to participants, for the unique healing properties of those plants. The concept of integration and its benefits, heavily emphasized in the clinical model, are typically absent from the ceremonial model.

A Clinical Spin

In contrast, the psychedelic-assisted therapy model aligns more closely with the Western psychological framework of meaning making, with the therapist serving as a support before, during, and after the experience. Here, the focus of a clinical mental health provider is based on a different set of assumptions, and is aimed at addressing specific mental health concerns of an individual, such as depression, anxiety, trauma, or addiction, using the psychedelic experience as a catalyst for deeper exploration and integration.

The psychotherapeutic context typically involves a more intimate dynamic between the client and the therapist(s), with a strong emphasis on the individual’s unique needs. The setting itself is often designed to be calm and welcoming—think soft lighting, comfortable furniture, and music designed to soothe and support the therapeutic process. During preparation sessions, the therapist helps to address expectations and intentions, making sure the client feels safe, comfortable, and ready to let go. While in dosing sessions the therapist talks a lot less, they must be equipped to handle any challenges that may arise and must be sensitive to the increased vulnerability, suggestibility and emotional impact of the psychedelics on the client. The therapist’s ability to understand and navigate the complexities of the psyche become crucial during integration, helping the client to confront pain, embody resilience, and make meaning of their experience. One of the advantages of psychedelic-assisted therapy is the potential for more individual psychological attention and support, within a more structured process, where the therapist can work closely with the client through all phases of the clinical approach.

Navigating the Overlap 

It’s important to note that ceremony and therapy share many qualities, and each approach can offer elements of the other. There are instances where ceremonial settings incorporate therapeutic elements, and vice versa, with facilitators or therapists blending modalities to create a more holistic experience.

The key is to recognize the unique strengths and limitations of each approach and to thoughtfully consider the needs and circumstances of the individual. For some, a ceremonial experience may be the optimal path, providing a deeper connection to the collective within a spiritual framework. For others, a clinically-informed psychedelic-assisted therapy model may be better suited to address specific mental health goals. Some people prefer communal group settings for healing over a more private, individualized setting. Ultimately, the choice between ceremony and therapy, or even a combination of the two, can be determined through the individual’s goals, their mental health history, and the training of the facilitators or therapists involved.

Conclusion

In the ever-changing landscape of psychedelic medicine, an integrative approach of diverse modalities can enhance the effectiveness and resilience of the therapeutic practice. As a clinician, a big part of this work is maintaining a curious, open mind that is attuned to the client. As a client, the effort lies in developing trust in one’s own intuition and inner wisdom. Honoring both the ceremonial and therapeutic realms can ensure access to the most suitable and empowering pathways for mind-body-spirit wellness.

Sara Reed, MS, LMFT

Sara Reed is a Licensed Marriage and Family Therapist and CEO of Mind’s iHealth Solutions, a digital health company that provides evidence based and culturally responsible mental health services for underserved groups. As a mental health futurist and clinical researcher, Sara examines the ways culture informs the way we diagnose and treat mental illness. Sara’s prior research work includes participation as a study therapist in psychedelic therapy research at Yale University and the University of Connecticut’s Health Center. Sara was the first Black therapist to provide MDMA-assisted psychotherapy in a clinical trial and continues to engage in ongoing advocacy work around health equity in psychedelic medicine.

https://psychiatryinstitute.com/wp-content/uploads/2019/11/Jeffrey-Guss.png

Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy and the treatment of substance use disorders. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psychedelic-assisted psychotherapy in the treatment of cancer-related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psychedelic-Assisted therapy in the treatment of Alcoholism, a collaborator with Yale University’s study on psychedelic-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS (Multidisciplinary Association for Psychedelic Studies) study on treatment of Post Traumatic Stress Disorder with Psychedelic-Assisted Psychotherapy. 

Dr. Guss is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He has published (with Elizabeth Nielson, PhD) a paper on “the influence of therapists’ first had experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training” in The Journal of Psychedelic Studies, August, 2018. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies and Supervisor in NYU’s Fellowship in Addiction Psychiatry. 

Dr. Guss maintains a private practice in New York City.

Will Van Derveer, MD

Will Van Derveer, MD is Co-Founder of Integrative Psychiatry Institute and Integrative Psychiatry Centers. Dr. Van Derveer was co-investigator on a phase 2 MAPS study of Psychedelic-assisted psychotherapy for treatment-resistant PTSD, and co-authored the publication of this study in 2018. He has also provided Psychedelic-assisted psychotherapy in two MAPS training studies. An active provider of KAP at his clinic in Boulder, CO, he has been teaching others KAP therapy for several years. Dr. Van Derveer contributed a chapter on mescaline in the 2021 "Handbook of Medical Hallucinogens" (edited by Charles Grob and Jim Grigsby). He is co-host of the Higher Practice Podcast.

Dr. Van Derveer regards unresolved emotional trauma as the most significant under-recognized root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass.


Scott has been a student of consciousness since his honors thesis on that topic at the University of Arizona in the 1970s under the tutelage of Dr. Andrew Weil. Following medical school, Scott studied Jungian therapy and acupuncture while working as a primary care physician in a rural area for four years. Psychedelic-assisted psychotherapy became a facet of his practice before this medicine was scheduled in 1985. He then completed a psychiatry residency at Columbia program in New York. Scott studied cross-cultural psychiatry and completed a child/adolescent psychiatry fellowship at the University of New Mexico.

In 2010 he founded Wholeness Center in Fort Collins. This innovative clinic provides cross-disciplinary evaluation and care for all mental health concerns. Scott serves as a site Principal Investigator and therapist for the Phase III trial of psychedelic-assisted psychotherapy for PTSD sponsored by (MAPS). He has also published numerous articles about his research on (CBD) in mental health. Currently, Scott works extensively with psychedelic-assisted-psychotherapy. He lectures all over the world to professional groups interested in a deeper look at mental health issues, safer tools, and a paradigm-shifting perspective about transformative care.

Will Van Derveer, MD is co-founder of Integrative Psychiatry Institute (IPI), along with friend and colleague Keith Kurlander, MA. He co-created IPI as an expression of what he stands for. First, that anyone can heal, and second that we medical providers must embrace our own healing journeys in order to fully command our potency as healers.

Dr. Van Derveer spent the last 20 years innovating and testing a comprehensive approach to addressing psychiatric challenges which transcends the conventional model he learned in medical school at Vanderbilt University and residency at University of Colorado, while deeply engaging his own healing path.

He founded the Integrative Psychiatric Healing Center in in 2001 in Boulder, CO, where he currently practices. Dr. Van Derveer regards unresolved emotional trauma as the most significant root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass. In addition to his clinical work and teaching, he was co-investigator in 2016 a Phase II randomized clinical trial, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). He continues to support this protocol, now in a Phase III clinical trial under break-through designation by FDA.

Dr. Van Derveer is a diplomate of the American Board of Integrative and Holistic Medicine (ABoIHM) since 2013, and he was board certified in the first wave of diplomates of the new American Board of Integrative Medicine (ABIM) in 2016.